XML 33 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Revenues:    
License and milestone fees $ 6,234 $ 13,167
Royalty revenue 4,166 2,053
Research and development support 776 1,990
Clinical materials revenue 2,027 8
Total revenues 13,203 17,218
Operating Expenses:    
Research and development 28,018 22,029
General and administrative 7,095 6,526
Total operating expenses 35,113 28,555
Loss from operations (21,910) (11,337)
Other (expense) income, net (372) 111
Net loss (22,282) (11,226)
Basic and diluted net loss per common share (in dollars per share) $ (0.26) $ (0.13)
Basic and diluted weighted average common shares outstanding (in shares) 85,872 85,010
Total comprehensive loss $ (22,282) $ (11,226)